Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

664
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
664
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

840
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
840
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

603
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
603
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

697
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
697
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

581
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
581
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

532
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
532

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adherence to ESGE guidelines on biliary stenting in malignant distal strictures: Results from a prospective Italian registry.

Endoscopy international open·2026
Same author

Long-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor on Nocturnal Cardiorespiratory Polygraphy Parameters in Patients with Cystic Fibrosis: A Prospective Study.

Life (Basel, Switzerland)·2025
Same author

Effect of Nirsevimab as a Primary Preventive Strategy on the Incidence, Severity, and Viral Etiology of Bronchiolitis: A Four-Year Observational Study.

Pediatric pulmonology·2025
Same author

Treatable Traits in Pediatric Interstitial Lung Diseases: Bridging the Gap to Tailored Therapeutics.

Journal of clinical medicine·2025
Same author

Mutations with residual CFTR function are associated with better glucose tolerance and insulin secretion in people with Cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025
Same author

Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.

Frontiers in pharmacology·2025

Related Experiment Video

Updated: Dec 24, 2025

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

860

Functional constipation masked as irritable bowel syndrome.

Monica Tosto1, Paola D'Andrea2, Ignazio Salamone3

  • 1Pediatric Gastroenterology and Cystic Fibrosis Unit, Policlinico G. Martino Hospital, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy.

BMC Gastroenterology
|April 8, 2020
PubMed
Summary
This summary is machine-generated.

Many children diagnosed with Irritable Bowel Syndrome with diarrhea (IBS-D) or mixed IBS (IBS-M) may actually have functional constipation. Treating constipation effectively resolved symptoms in most cases, suggesting a re-evaluation of diagnoses.

Keywords:
Abdominal painDiarrheaFunctional constipationFunctional gastrointestinal disordersIrritable bowel syndromeOccult constipation

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.0K
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.6K

Related Experiment Videos

Last Updated: Dec 24, 2025

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

860
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.0K
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.6K

Area of Science:

  • Pediatric Gastroenterology
  • Functional Gastrointestinal Disorders

Background:

  • Rome IV criteria recommend treating constipation in children suspected of Irritable Bowel Syndrome with Constipation (IBS-C).
  • This study investigated if functional constipation is misdiagnosed as Irritable Bowel Syndrome with diarrhea (IBS-D) or Irritable Bowel Syndrome with mixed pattern (IBS-M).

Purpose of the Study:

  • To determine if functional constipation is misdiagnosed as IBS-D or IBS-M in pediatric patients.
  • To assess the efficacy of treating presumed functional constipation in children diagnosed with IBS-D or IBS-M.

Main Methods:

  • Prospective enrollment of 10 children with IBS-D and 16 with IBS-M based on Rome IV criteria.
  • Children with suspected "occult constipation" received Polyethylene glycol 3350 bowel cleansing, followed by re-evaluation at 2 months and 6 months follow-up.
  • A control group of 16 children with IBS-C was included for comparison.

Main Results:

  • 80% of IBS-D and 87% of IBS-M patients met endpoints, showing reduced abdominal pain and resolved diarrhea.
  • Treatment response in IBS-D and IBS-M groups was comparable to the IBS-C control group (93% response).

Conclusions:

  • A significant number of pediatric patients diagnosed with IBS-D or IBS-M may have undiagnosed functional constipation.
  • Management of functional constipation should be considered for children presenting with IBS-D or IBS-M symptoms.